Patent Assignment
Reel/Frame 075712/0291
Assignment of Assignor's Interest
Recorded: 2026-06-11
Pages: 7
Assignor
NOVARTIS AG
Executed: 2025-12-19
Assignee
NOVARTIS PHARMA AG
LICHTSTRASSE 35, BASEL, 4056, SWITZERLAND
Covered Properties
(47)
Interleukin-17 (Il-17) Antagonistic Antibodies
Application:
18/647,368 →
Publication:
US US20250122277A1
Methods of Treating Psoriasis Using Il-17 Antagonists
Application:
18/061,227 →
Publication:
US US20230321231A1
Methods of Treating Chronic Inflammatory Disease with Secukinumab
Methods of Treating Psoriasis with Secukinumab
Methods of Treating Psoriasis with Secukinumab
Apparatus for Producing Capacitor Element Member
Digital Image Sharing
Application:
11/534,491 →
Publication:
US US20080079984A1
Touch Sensing Substrate and Touch Sensing Liquid Crystal Display
Methods of Treating Inflammatory Arthritis Using Il-17 Antagonists
Methods of Treating Ankylosing Spondylitis Using Il-17 Antagonists
Application:
18/061,221 →
Publication:
US US20230346926A1
Methods of Treating Ankylosing Spondylitis Using Il-17 Antagonists
Application:
18/048,797 →
Publication:
US US20230293683A1
Methods of Treating Psoriatic Arthritis Using Il-17 Antagonists
Application:
19/389,528 →
Publication:
US US20260077042A1
Use of Il-17 Antagonists to Inhibit the Progression of Structural Damage in Psoriatic Arthritic Patients
Application:
17/672,242 →
Publication:
US US20220313818A1
Methods of Treating Non-Radiographic Axial Spondyloarthritis Using Interleukin-17 (Il-17) Antagonists
Application:
15/766,043 →
Publication:
US US20190330328A1
Methods of Treating Non-Radiographic Axial Spondyloarthritis Using Interleukin-17 (Il-17) Antagonists
Application:
18/628,097 →
Publication:
US US20250066466A1
Method of Treating Hidradentitis Suppurativa with Il-17 Antagonists
Application:
16/761,513 →
Publication:
US US20200277369A1
Methods of Treating Autoimmune Diseases Using Interleukin-17 (Il-17) Antagonists
Methods of Treating Autoimmune Diseases Using Interleukin-17 (Il-17) Antagonists
Application:
19/304,006 →
Publication:
US US20260159581A1
Pharmaceutical Products and Stable Liquid Compositions of Il-17 Antibodies
Pharmaceutical Products and Stable Liquid Compositions of Il-17 Antibodies
Pharmaceutical Products and Stable Liquid Compositions of Il-17 Antibodies
Selective Reduction of Cysteine Residues in Il-17 Antibodies
Application:
17/683,888 →
Publication:
US US20220315650A1
Selective Reduction of Cysteine Residues in Il-17 Antibodies
Application:
18/800,977 →
Publication:
US US20250034241A1
Selective Reduction of Cysteine Residues in Il-17 Antibodies
Application:
19/065,656 →
Publication:
US US20260116964A1
Methods for Reducing the Oxidation Level of Cysteine Residues in a Secreted Recombinantly-Expressed Protein During Cell Culture
Application:
17/557,921 →
Publication:
US US20220251502A1
Antibodies to PMEL17 and Conjugates Thereof
Application:
18/454,457 →
Publication:
US US20240189439A1
Antibodies to PMEL17 and Conjugates Thereof
Application:
18/672,871 →
Publication:
US US20240299574A1
Hypersialylating Cells
Application:
18/557,772 →
Publication:
US US20240239871A1
IMPROVED PROTEIN PRODUCTION USING miRNA TECHNOLOGY
Application:
18/866,727 →
Publication:
US US20250313878A1
Il-17 Antagonistic Antibodies
Il-17 Antagonistic Antibodies
IL-17 Antibodies
IL-17 Antagonistic Antibodies
IL-17 Antagonistic Antibodies
Methods of Treating Psoriasis Using Il-17 Antibody
Methods of Treating Psoriasis Using Il-17 Antibodies
Methods of Treating Psoriasis Using Il-17 Antagonists
Methods of Treating Ankylosing Spondylitis Using Il-17 Antagonists
Use of Il-17 Antagonists to Inhibit the Progression of Structural Damage in Psoriatic Arthritis Patients
Pharmaceutical Products and Stable Liquid Compositions of Il-17 Antibodies
Pharmaceutical Products and Stable Liquid Compositions of Il-17 Antibodies
Pharmaceutical Products and Stable Liquid Compositions of Il-17 Antibodies
Pharmaceutical Products and Stable Liquid Compositions of Il-17 Antibodies
Selective Reduction of Cysteine Residues in Il-17 Antibodies
Methods for Purification of Antibodies Using Aliphatic Alcohols
Multi-Copy Gene Protein Expression System
Selection Vectors and Methods of Selecting Eukaryotic Host Cells
Related Assignments
(25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Mar 3, 2003
From: NITOH, HIROSHI; OKABE, TOSHIHIRO; ISHII, KENJI; SAKAI, ATSUSHI
To: SHOWA DENKO K.K.
Reel/Frame 014039/0990 →
Assignment of Assignor's Interest
Jan 3, 2007
From: GALLUCCI, FRANK V
To: FUJIFILM E-SYSTEMS, INC.
Reel/Frame 018702/0172 →
Assignment of Assignor's Interest
May 21, 2009
From: LO, CHENG; CHENG, CHING-SHENG; LIN, YUNG-LUN; HU, CHIH-JEN
To: AU OPTRONICS CORPORATION
Reel/Frame 022715/0696 →
Change of Name
Jan 14, 2010
From: FUJIFILM U.S.A., INC.
To: FUJIFILM NORTH AMERICA CORPORATION
Reel/Frame 023787/0831 →
Merger
Jan 14, 2010
From: FUJIFILM E-SYSTEMS, INC.
To: FUJIFILM U.S.A., INC.
Reel/Frame 023787/0615 →
Assignment of Assignor's Interest
Feb 18, 2010
From: SHOWA DENKO K.K.
To: MURATA MANUFACTURING CO., LTD.
Reel/Frame 023950/0728 →
Assignment of Assignor's Interest
Apr 6, 2018
From: RICHARDS, HANNO
To: NOVARTIS PHARMA AG
Reel/Frame 045460/0199 →
Assignment of Assignor's Interest
Apr 6, 2018
From: NOVARTIS PHARMA GMBH
To: NOVARTIS AG
Reel/Frame 045460/0051 →
Assignment of Assignor's Interest
Apr 6, 2018
From: MANN, CHRISTIAN
To: NOVARTIS PHARMA GMBH
Reel/Frame 045459/0933 →
Assignment of Assignor's Interest
Apr 6, 2018
From: PORTER, BRIAN
To: NOVARTIS PHARMACEUTICALS CORPORATION
Reel/Frame 045460/0111 →
Assignment of Assignor's Interest
Apr 6, 2018
From: NOVARTIS PHARMACEUTICALS CORPORATION
To: NOVARTIS AG
Reel/Frame 045460/0157 →
Assignment of Assignor's Interest
Apr 6, 2018
From: NOVARTIS PHARMA AG
To: NOVARTIS AG
Reel/Frame 045460/0255 →
Assignment of Assignor's Interest
May 6, 2020
From: NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.
To: NOVARTIS AG
Reel/Frame 052579/0249 →
Assignment of Assignor's Interest
May 6, 2020
From: NOVARTIS PHARMACEUTICALS CORPORATION
To: NOVARTIS AG
Reel/Frame 052579/0263 →
Assignment of Assignor's Interest
May 6, 2020
From: BRUIN, GERGARD
To: NOVARTIS INSTITUTE FOR BIOMEDICAL RESEARCH, INC.
Reel/Frame 052579/0240 →
Assignment of Assignor's Interest
May 6, 2020
From: NOVARTIS PHARMA AG
To: NOVARTIS AG
Reel/Frame 052583/0909 →
Assignment of Assignor's Interest
May 6, 2020
From: EZZET, FARKAD
To: NOVARTIS PHARMACEUTICALS CORPORATION
Reel/Frame 052579/0235 →
Assignment of Assignor's Interest
May 6, 2020
From: DE VERA JUAREZ, ANA MARIA; LOESCHE, CHRISTIAN
To: NOVARTIS PHARMA AG
Reel/Frame 052579/0218 →
Assignment of Assignor's Interest
Feb 23, 2022
From: NOVARTIS PHARMACEUTICALS CORPORATION
To: NOVARTIS AG
Reel/Frame 059072/0427 →
Assignment of Assignor's Interest
Feb 23, 2022
From: MPOFU, SHEPHARD; RICHARDS, HANNO
To: NOVARTIS PHARMA AG
Reel/Frame 059072/0293 →
Assignment of Assignor's Interest
Feb 23, 2022
From: LIGOZIO, GREGORY
To: NOVARTIS PHARMACEUTICALS CORPORATION
Reel/Frame 059071/0905 →
Assignment of Assignor's Interest
Feb 23, 2022
From: NOVARTIS PHARMA AG
To: NOVARTIS AG
Reel/Frame 059072/0469 →
Assignment of Assignor's Interest
May 26, 2022
From: NOVARTIS PHARMACEUTICALS CORPORATION
To: NOVARTIS AG
Reel/Frame 060029/0510 →
Assignment of Assignor's Interest
May 26, 2022
From: PRICOP, LUMINITA
To: NOVARTIS PHARMACEUTICALS CORPORATION
Reel/Frame 060029/0155 →
Assignment of Assignor's Interest
May 26, 2022
From: MENDELSON, MERYL
To: NOVARTIS PHARMACEUTICALS CORPORATION
Reel/Frame 060029/0070 →